Who can prescribe Strattera? NP vs MD in Florida

If you’re considering treatment for ADHD but wondering whether you can access non-stimulant medications like Strattera (atomoxetine) through telehealth, you’re not alone. Millions of Americans are turning to virtual care for mental health treatment, and ADHD management has become one of the most sought-after telehealth services.

The short answer: Yes, you can get ADHD non-stimulant medication through telehealth in most cases. Since medications like Strattera aren’t controlled substances, they’re not subject to the strict federal prescribing restrictions that apply to stimulant medications like Adderall or Ritalin.

In this comprehensive guide, we’ll walk you through everything you need to know about accessing ADHD non-stimulant treatment via telehealth—from federal regulations and state-specific rules to what you can expect during your virtual appointment.

Understanding ADHD Non-Stimulant Medications

Before diving into telehealth regulations, it’s important to understand what non-stimulant ADHD medications are and how they differ from their stimulant counterparts.

What Are Non-Stimulant ADHD Medications?

Non-stimulant medications treat ADHD through different mechanisms than traditional stimulants. The most common non-stimulant options include:

• Strattera (atomoxetine): A selective norepinephrine reuptake inhibitor (SNRI) that helps improve attention and reduce impulsivity
• Intuniv (guanfacine): An alpha-2 adrenergic agonist that affects certain receptors in the brain
• Kapvay (clonidine): Another alpha-2 agonist, often used alongside other ADHD treatments

Strattera is the most commonly prescribed non-stimulant for ADHD and will be our primary focus throughout this guide.

Why Non-Stimulants Matter for Telehealth Access

Here’s the critical distinction: Strattera is not a controlled substance. According to the FDA and DEA classifications, atomoxetine carries no abuse potential and isn’t tracked under the Controlled Substances Act. This means it isn’t subject to the Ryan Haight Act’s requirement for an in-person medical evaluation before prescribing via telehealth.

This classification makes non-stimulants significantly more accessible through virtual care platforms compared to Schedule II stimulants like Adderall or Vyvanse, which face stricter prescribing requirements.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Federal Telehealth Regulations for ADHD Medications

Understanding the federal regulatory landscape is essential for anyone seeking ADHD treatment online.

The Current State of DEA Telehealth Rules

As of December 2025, the Drug Enforcement Administration (DEA) has extended pandemic-era telehealth flexibilities through December 31, 2025. This ‘Third Temporary Extension’ allows healthcare providers to prescribe Schedule II-V controlled substances via telehealth without requiring a prior in-person examination.

However, this extension primarily affects stimulant medications. Since Strattera and other non-stimulants aren’t controlled substances, they’ve never been restricted by these federal telehealth rules in the first place.

What Happens in 2026?

The DEA is currently reviewing options for 2026, with a potential fourth extension under consideration. If no new rule is finalized by January 1, 2026, the in-person exam requirements under the Ryan Haight Act could resume for controlled substances.

For patients seeking non-stimulant ADHD medications, these potential changes are less concerning. Providers have always been able to prescribe Strattera and similar medications through telehealth under standard medical practice guidelines.

The Ryan Haight Act: What You Need to Know

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 was designed to prevent illegal online pharmacies from distributing controlled substances. It requires an in-person medical evaluation before prescribing controlled medications via the internet.

Key point: This act doesn’t apply to non-controlled medications like Strattera. A licensed provider can evaluate you through video, confirm an ADHD diagnosis, and e-prescribe Strattera if clinically appropriate—no in-person visit required by federal law.

State-by-State Telehealth Rules for ADHD Treatment

While federal regulations set the baseline, individual states have their own telehealth laws that can significantly impact your access to care. Let’s examine how major states handle ADHD medication prescribing via telehealth.

California: Broad Telehealth Access

In-person requirement: None for non-controlled medications

California has embraced telehealth with relatively few restrictions. Providers can prescribe Strattera and other non-stimulant ADHD medications after a comprehensive video evaluation that meets the state’s ‘good faith exam’ standard. The telehealth examination satisfies this requirement—you don’t need a separate in-person appointment.

For controlled stimulants, California requires providers to check the Prescription Drug Monitoring Program (PDMP) every four months, but this doesn’t affect non-stimulant prescribing.

New York: Stricter Controlled Substance Rules

In-person requirement: Required for controlled substances only (not applicable to Strattera)

New York implemented stricter telehealth rules in May 2025, requiring an initial in-person evaluation before prescribing any controlled substance via telemedicine. However, this rule doesn’t affect non-stimulant medications.

If you’re a New York resident seeking Strattera through telehealth, you can proceed with a virtual-only consultation. The new in-person requirement only applies if your provider later determines you need a controlled stimulant medication.

Florida: Mental Health Exception

In-person requirement: None for psychiatric conditions (including ADHD)

Florida has specific regulations around Schedule II controlled substances, generally prohibiting telehealth prescribing except for psychiatric conditions—and ADHD qualifies. This means both stimulants and non-stimulants can be prescribed via telehealth in Florida.

For non-controlled medications like Strattera, there are no special restrictions. Florida does require providers to check the PDMP before every controlled substance prescription, but this is a provider responsibility that doesn’t affect your ability to access care.

Texas: Mental Health Friendly

In-person requirement: None for ADHD treatment

Texas is notably progressive with telehealth for mental health and chronic conditions. There’s no blanket in-person requirement for ADHD treatment via telemedicine.

One caveat: Texas limits nurse practitioners’ and physician assistants’ ability to prescribe Schedule II stimulants in outpatient settings—they can only do so in hospitals or hospice care. However, physicians can prescribe any ADHD medication via telehealth, and NPs/PAs can freely prescribe non-stimulants like Strattera under their collaborative practice agreements.

Alabama: Most Restrictive

In-person requirement: Annual visit required for ongoing care (with mental health exception)

Alabama has some of the nation’s strictest telehealth rules. The state generally requires an in-person visit within 12 months for ongoing telehealth treatment. However, there’s an important exception: mental health services are exempt from this requirement.

Since ADHD is classified as a mental health condition, you may be able to receive ongoing Strattera prescriptions via telehealth in Alabama without the annual in-person visit. Always verify current practices with your Alabama-licensed provider, as interpretations can vary.

New Hampshire: Recently Expanded Access

In-person requirement: Annual follow-up (can be virtual)

New Hampshire significantly expanded telehealth access in August 2025 by removing its previous in-person requirement. Now, providers must conduct at least an annual follow-up evaluation for patients receiving controlled medications via telemedicine, but this evaluation can be conducted through telehealth.

For non-controlled medications like Strattera, standard care guidelines apply with no special restrictions.

Who Can Prescribe ADHD Medications via Telehealth?

Understanding which providers can prescribe ADHD medications through virtual visits is crucial when choosing a telehealth platform.

Physicians (MD/DO)

Licensed physicians can prescribe both stimulant and non-stimulant ADHD medications via telehealth in all 50 states, provided they:

• Hold an active medical license in your state
• Have a valid DEA registration (if prescribing controlled substances)
• Follow state-specific telehealth and prescribing regulations
• Meet standard-of-care requirements for evaluation and diagnosis

Nurse Practitioners (NPs)

Nurse practitioner prescribing authority varies significantly by state:

Independent practice states (including New York, New Hampshire, Illinois): NPs can prescribe all ADHD medications, including Schedule II stimulants, after completing required training and experience hours.

Collaborative practice states (including California, Florida, Pennsylvania): NPs work under physician collaborative agreements. They can generally prescribe non-stimulants freely but may face restrictions on stimulant prescribing.

Restricted states (including Georgia, Alabama, Texas for outpatient settings): NPs face significant limitations on Schedule II prescribing, though they can typically prescribe non-controlled medications like Strattera.

Physician Assistants (PAs)

Physician assistants practice under supervising physician agreements in all states. Their prescribing authority depends on:

• State-specific regulations
• The scope of their supervisory agreement
• Additional certifications or training requirements

Most PAs can prescribe non-stimulant ADHD medications across all states when working within an appropriate supervisory relationship.

What to Expect During Your Telehealth ADHD Evaluation

If you’re considering telehealth for ADHD treatment, understanding the evaluation process will help you prepare and ensure you receive appropriate care.

Comprehensive Assessment

Legitimate telehealth providers conduct thorough ADHD evaluations that mirror in-person assessments. Expect your provider to:

Review your symptom history: You’ll discuss when symptoms began (ADHD must have onset before age 12), how they’ve affected different life areas, and whether symptoms occur in multiple settings (home, work, school).

Use standardized screening tools: Many providers use validated ADHD rating scales like the Adult ADHD Self-Report Scale (ASRS) or Conners’ rating scales.

Assess for co-occurring conditions: Depression, anxiety, and other mental health conditions commonly occur alongside ADHD. Your provider will screen for these to ensure comprehensive treatment planning.

Review medical history: Expect questions about cardiovascular health, liver function, past medication trials, and any history of substance use. This helps determine which medications are safe and appropriate for you.

Discuss treatment goals: Your provider should explore what you hope to achieve with treatment—improved focus at work, better organization, reduced impulsivity, etc.

Documentation Requirements

Be prepared to provide:

• Government-issued photo identification (to verify identity and state residency)
• Previous medical records, if available
• School records or performance evaluations (particularly helpful for adult ADHD diagnosis)
• List of current medications and supplements
• Insurance information (if applicable)

Some telehealth platforms request that a family member or someone who knows you well participate in part of the evaluation to corroborate symptom history, particularly for adult ADHD diagnosis.

The Prescription Process

If your provider determines that Strattera or another non-stimulant is appropriate, they’ll:

1. Discuss medication options: You’ll learn about how Strattera works, expected timelines (full effects typically take 4-6 weeks), potential side effects, and monitoring requirements.

2. Check for contraindications: Your provider will ensure you don’t have conditions that make Strattera unsafe, such as narrow-angle glaucoma, recent MAOI use, or severe cardiovascular disease.

3. Create a treatment plan: This includes starting dose, follow-up schedule, and what to monitor between appointments.

4. Send an e-prescription: Your provider will electronically transmit the prescription to your chosen pharmacy. Since Strattera isn’t controlled, it can typically be prescribed with refills (unlike stimulants that require monthly prescriptions).

Follow-Up Care

Quality telehealth ADHD treatment doesn’t end with a prescription. Expect:

• Initial follow-up within 2-4 weeks: To assess early response, side effects, and any necessary dose adjustments
• Regular check-ins: Monthly or quarterly appointments to monitor effectiveness and safety
• Symptom tracking: Many providers ask patients to use rating scales or symptom diaries between visits
• Coordination with other providers: Your telehealth prescriber may communicate with your primary care doctor or therapist

Strattera vs. Stimulants: Why Your Provider Might Recommend a Non-Stimulant

Understanding when non-stimulant medications are preferred can help you have more informed conversations with your provider.

When Non-Stimulants Are First-Line Treatment

Your provider may recommend starting with Strattera if you:

• Have a personal or family history of substance abuse
• Experience anxiety that could worsen with stimulants
• Have cardiovascular concerns (high blood pressure, heart rhythm issues)
• Are concerned about controlled substance regulations
• Experience significant side effects from stimulants
• Prefer once-daily medication with smoother, all-day coverage
• Want medication that doesn’t affect appetite or sleep as dramatically

Advantages of Strattera for Telehealth Patients

No monthly prescription requirement: Unlike Schedule II stimulants that require a new prescription each month (no refills allowed), Strattera can be prescribed with multiple refills, reducing administrative burden.

Fewer prescribing restrictions: As discussed throughout this guide, non-controlled status means more straightforward telehealth access across all states.

No DEA concerns: You won’t face potential treatment interruptions if DEA telehealth rules change in 2026.

Lower stigma risk: Some patients feel more comfortable with non-controlled medications, particularly if they’re concerned about workplace drug testing or travel with medication.

When Stimulants Might Be Necessary

It’s important to note that stimulant medications remain first-line treatment for many ADHD patients because they’re often more effective. If Strattera doesn’t adequately control your symptoms after an appropriate trial (typically 6-8 weeks at therapeutic dose), your provider may recommend:

• Transitioning to a stimulant medication
• Adding a second medication
• Coordinating with a local psychiatrist for in-person evaluation if your state requires it for controlled substances

Choosing a Reputable Telehealth ADHD Provider

The telehealth ADHD space has faced scrutiny following investigations into companies that allegedly over-prescribed stimulants without adequate oversight. Here’s how to identify quality providers.

Red Flags to Avoid

Guaranteed prescriptions: Legitimate providers never guarantee medication before evaluation. If a service promises you’ll get ADHD medication, that’s a warning sign.

Minimal evaluation: A 5-10 minute chat or simple questionnaire isn’t sufficient for ADHD diagnosis. Expect at least 45-60 minutes for an initial evaluation.

No follow-up requirements: Responsible prescribers schedule regular follow-ups to monitor medication effectiveness and safety.

Pressure to choose stimulants: Providers should discuss all treatment options, including non-medication approaches and non-stimulants.

Vague licensing information: You should be able to verify that your provider is licensed in your state.

What Quality Telehealth Looks Like

Look for platforms that:

• Use licensed MDs, DOs, or NPs with appropriate state licensure
• Require live video consultations (not just phone or messaging)
• Follow DSM-5 diagnostic criteria for ADHD
• Offer or coordinate therapy services alongside medication
• Have transparent pricing and privacy policies
• Coordinate with your existing healthcare providers
• Comply with HIPAA and maintain secure patient records

How Klarity Health Prioritizes Patient Safety

At Klarity Health, we’ve built our ADHD treatment program around comprehensive care and patient safety:

Thorough evaluations: Our providers conduct detailed video assessments using validated screening tools and DSM-5 criteria. We take the time to understand your full clinical picture before making treatment recommendations.

Licensed in your state: We match you with psychiatrists, psychiatric nurse practitioners, or physician assistants who hold active licenses in your state and are familiar with local regulations.

Flexible treatment options: Our providers prescribe both stimulant and non-stimulant ADHD medications when clinically appropriate. We also emphasize the importance of behavioral strategies and can connect you with therapy services.

Transparent pricing: Whether you’re using insurance or paying out of pocket, you’ll know costs upfront. We accept most major insurance plans and offer affordable self-pay rates starting at $269 for the initial psychiatric evaluation.

Provider availability: We typically offer appointment availability within days, not weeks or months—because we know ADHD symptoms affect your daily life and timely treatment matters.

Ongoing support: ADHD treatment is a journey, not a one-time prescription. We provide regular follow-ups, medication adjustments as needed, and coordination with your other healthcare providers.

Practical Tips for Telehealth ADHD Patients

Before Your Appointment

1. Gather documentation: Collect any previous ADHD assessments, report cards, performance reviews, or medical records that demonstrate symptom history.

2. Write down your symptoms: Create a list of specific examples of how ADHD affects your work, relationships, and daily functioning.

3. List previous treatments: Note any medications you’ve tried, including doses and how they worked (or didn’t).

4. Prepare your environment: Find a private, quiet space with good lighting and internet connection for your video visit.

5. Have your insurance information ready: If using insurance, have your card and any required referrals available.

During Treatment

1. Be honest about your experience: Share both positive changes and concerning side effects. Your provider can only help if they know what’s really happening.

2. Track your symptoms: Many patients find it helpful to use a daily rating system (1-10 scale) for focus, impulsivity, and other symptoms.

3. Monitor side effects: Common Strattera side effects include decreased appetite, nausea, fatigue, and dry mouth, especially when starting. Report persistent or severe side effects.

4. Give medication time: Strattera takes 4-6 weeks to reach full effectiveness, unlike stimulants that work the first day. Don’t give up prematurely.

5. Attend follow-ups: Regular check-ins allow your provider to optimize your treatment and catch problems early.

Managing Your Prescription

1. Use one pharmacy consistently: This helps pharmacists catch potential drug interactions and builds a relationship for questions.

2. Set refill reminders: Even though Strattera can be prescribed with refills, set calendar reminders so you don’t run out.

3. Store medication properly: Keep in a cool, dry place, away from children, in its original container.

4. Know your insurance coverage: If using insurance, understand your coverage for mental health medications and any prior authorization requirements.

5. Plan for travel: Strattera isn’t controlled, so traveling with it is straightforward—just keep it in the prescription bottle. For extended trips, ensure you have enough medication.

The Future of ADHD Telehealth: What to Watch in 2026

The landscape of ADHD telehealth continues to evolve. Here’s what may change and how to prepare.

Potential DEA Regulatory Changes

The current DEA extension expires December 31, 2025. Three possible scenarios for 2026:

Scenario 1: Fourth extension: The DEA continues current telehealth flexibilities, maintaining status quo for controlled substance prescribing. (A fourth extension is currently under OMB review.)

Scenario 2: Special registration system: The DEA implements its proposed ‘Special Registration’ rule, creating permanent telehealth pathways with additional safeguards for controlled substances.

Scenario 3: Return to Ryan Haight requirements: Without new rules, the original in-person exam requirement could resume for stimulant prescriptions.

What this means for non-stimulant patients: Regardless of which scenario unfolds, non-stimulant prescribing through telehealth should remain unaffected. Strattera and similar medications were never restricted by these federal rules.

State-Level Changes to Monitor

Several states are considering telehealth legislation:

• California AB 1503: Would further clarify that telehealth examinations satisfy prescription requirements
• Texas HB 1948: Could expand NP Schedule II prescribing authority in outpatient settings
• Multiple states: Ongoing discussions about PDMP integration, e-prescribing mandates, and telehealth parity

How to Stay Informed

1. Ask your provider: Telehealth platforms will notify patients of regulatory changes that affect their care.

2. Check state medical boards: Your state medical board website publishes updates on telehealth regulations.

3. Follow reputable sources: Healthcare law blogs and medical associations provide analysis of regulatory changes.

4. Plan ahead: If you’re on stimulant medication through telehealth, discuss backup plans with your provider in case regulations require an in-person visit.

Common Questions About ADHD Telehealth

Can I get an ADHD diagnosis through telehealth?

Yes. Qualified providers can diagnose ADHD through comprehensive video evaluations using the same DSM-5 criteria applied in person. The evaluation includes symptom assessment, developmental history, functional impairment review, and screening for other conditions.

Will my insurance cover telehealth ADHD treatment?

Most insurance plans now cover telehealth mental health services at the same rate as in-person visits. However, coverage specifics vary by plan. Klarity Health accepts most major insurance plans and can verify your benefits before your appointment.

What if I need a controlled stimulant medication instead?

If your provider determines that a stimulant would be more effective, they can prescribe it through telehealth under current federal rules (through December 2025, with likely extension). Some states may have additional requirements—your provider will guide you through any necessary steps.

Can I switch from in-person to telehealth care?

Absolutely. If you’re currently seeing a psychiatrist in person for ADHD treatment, you can transition to telehealth. Many patients find this more convenient for routine medication management, reserving in-person visits for more complex situations.

What if I move to a different state?

Healthcare providers must be licensed in the state where you’re physically located during the appointment. If you move, you’ll need to transfer care to a provider licensed in your new state. Klarity Health operates in multiple states and can often facilitate these transitions.

How much does telehealth ADHD treatment cost?

Costs vary by provider and whether you use insurance. At Klarity Health:

• Initial psychiatric evaluation: Starting at $269 self-pay
• Follow-up visits: Typically $99-$129
• Insurance accepted: We accept most major plans, with copays/coinsurance based on your specific coverage

Can children get ADHD treatment through telehealth?

Many telehealth platforms treat adolescents (typically 13+) for ADHD. Younger children generally benefit from in-person pediatric evaluations. Age policies vary by provider—check with your chosen platform about minimum age requirements.

Taking the Next Step

If you’re struggling with ADHD symptoms, telehealth offers a convenient, effective pathway to treatment—particularly for non-stimulant medications like Strattera that aren’t subject to complex controlled substance regulations.

Getting Started with Klarity Health

Klarity Health makes accessing ADHD treatment straightforward:

1. Create your account: Takes just minutes on our secure platform
2. Complete a brief assessment: Helps us understand your symptoms and treatment goals
3. Schedule your appointment: Usually available within days
4. Meet your provider: Comprehensive video evaluation with a licensed clinician in your state
5. Receive your treatment plan: If appropriate, medications can be prescribed and sent to your pharmacy the same day
6. Ongoing support: Regular follow-ups to optimize your treatment

Our providers have the expertise to evaluate whether non-stimulant or stimulant medication is right for you, and we stay current on all regulatory requirements across the states we serve.

You’re Not Alone

Living with untreated ADHD affects every aspect of life—work performance, relationships, self-esteem, and overall well-being. Telehealth has made evidence-based treatment more accessible than ever, removing barriers like transportation challenges, long wait times, and scheduling difficulties.

Whether Strattera or another ADHD medication proves right for you, taking that first step toward evaluation is what matters. At Klarity Health, we’re here to support you through the entire process, from initial diagnosis through ongoing medication management and beyond.

Ready to take control of your ADHD? Schedule your evaluation with Klarity Health today and discover how personalized, convenient telehealth treatment can help you thrive.

References

1. FierceHealthcare. ‘DEA finalizes one-year extension of controlled substance prescribing via telehealth, punts final rule.’ November 2024. https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final

2. McDermott Will & Emery. ‘DEA Signals Extension of Telemedicine Flexibilities for Controlled Substance Prescribing for 2026.’ 2025. https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/

3. Sheppard Mullin Healthcare Law Blog. ‘Telehealth and In-Person Visits: Tracking Federal and State Updates to Pandemic-Era Telehealth Exceptions.’ National Law Review, August 15, 2025. https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/

4. RxAgent. ‘The Telehealth Compliance Trap: What ADHD Patients Need to Know Before 2026.’ October 2025. https://www.rxagent.co/blog/telehealth-compliance-trap

5. Medical News Today. ‘Is Strattera a controlled substance?’ January 14, 2025. https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance

This article was last updated December 17, 2025. Telehealth regulations continue to evolve. Always verify current rules with your healthcare provider and state medical board. This content is for informational purposes only and doesn’t constitute medical advice. Consult with a qualified healthcare provider about your specific situation.

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment